Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SQZ-AAC-HPV |
Synonyms | |
Therapy Description |
SQZ-AAC-HPV is a cell therapy comprised of autologous red blood cells engineered to express tumor-specific antigens (TAA) and human papillomavirus (HPV) type 16 epitopes and carrying a Toll-like receptor (TLR) agonist as an adjuvant, with potential to induce an anti-tumor immune response against HPV16- or TAA-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SQZ-AAC-HPV | Engineered AAC Loaded with HPV16 Epitopes | SQZ-AAC-HPV is a cell therapy comprised of autologous red blood cells engineered to express tumor-specific antigens (TAA) and human papillomavirus (HPV) type 16 epitopes and carrying a Toll-like receptor (TLR) agonist as an adjuvant, with potential to induce an anti-tumor immune response against HPV16- or TAA-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04892043 | Phase I | Ipilimumab + SQZ-AAC-HPV SQZ-AAC-HPV Ipilimumab + Nivolumab + SQZ-AAC-HPV | Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |